HTG Molecular Diagnostics, Inc.
Other OTCTotal Valuation
HTG Molecular Diagnostics, Inc. carries a market capitalization of 221.00, placing it among publicly traded companies globally. Its enterprise value stands at -2.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 221.00 |
| Enterprise Value | -2.34M |
Share Statistics
HTG Molecular Diagnostics, Inc. currently has 2.21M shares outstanding.
| Shares Outstanding | 2.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.04, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.04 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | -0.01 |
| P/OCF Ratio | -0.01 |
Enterprise Valuation
| EV / Sales | 2.25 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
HTG Molecular Diagnostics, Inc. maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 838.92, indicating elevated leverage, while an interest coverage ratio of -25.61 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.40 |
| Quick Ratio | 1.17 |
| Debt / Equity | 838.92 |
| Debt / EBITDA | -0.21 |
| Interest Coverage | -25.61 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -102.48 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.64 |
Taxes
| Income Tax | 12,669.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
HTG Molecular Diagnostics, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, HTG Molecular Diagnostics, Inc. generated 6.21M in revenue and converted that into -20.15M in net income, yielding earnings per share of -14.92. EBITDA reached -19.10M, while operating income came in at -19.59M.
| Revenue | 6.21M |
| Gross Profit | 1.35M |
| Operating Income | -19.59M |
| Pretax Income | -20.14M |
| Net Income | -20.15M |
| EBITDA | -19.10M |
| EBIT | -19.59M |
| Earnings Per Share (EPS) | -14.92 |
Balance Sheet
HTG Molecular Diagnostics, Inc. holds 6.56M in cash and equivalents against 3.98M in total debt, resulting in a net debt position of 79,097.00. Total book value stands at -234.98M, with working capital of 2.63M providing operational flexibility.
| Cash & Cash Equivalents | 6.56M |
| Total Debt | 3.98M |
| Net Debt | 79,097.00 |
| Equity (Book Value) | -234.98M |
| Book Value Per Share | -173.99 |
| Working Capital | 2.63M |
Cash Flow
HTG Molecular Diagnostics, Inc. produced -16.83M in operating cash flow over the past twelve months. After subtracting -20,867.00 in capital expenditures, free cash flow totaled -16.85M - equivalent to -12.48 per share.
| Operating Cash Flow | -16.83M |
| Capital Expenditures | -20,867.00 |
| Free Cash Flow | -16.85M |
| FCF Per Share | -12.48 |
Margins
HTG Molecular Diagnostics, Inc. operates with a gross margin of 21.69, reflecting its pricing power and cost economics. The operating margin of -315.21 and net profit margin of -324.28 provide insight into operational efficiency.
| Gross Margin | 21.69 |
| Operating Margin | -315.21 |
| Pretax Margin | -324.08 |
| Profit Margin | -324.28 |
| EBITDA Margin | -307.36 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -711.11 |
| FCF Yield | -6,915.30 |
Stock Splits
HTG Molecular Diagnostics, Inc.'s most recent stock split took place on December 21, 2022 with a 12:1 split ratio.
| Last Split Date | 12/21/2022 |
| Split Ratio | 12:1 |
Scores
HTG Molecular Diagnostics, Inc. posts an Altman Z-Score of -35.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -35.35 |